| Upgrades | Neutral Buy | X | ||
|
$236 $422 |
||||
| Reiterated | Buy | X | ||
|
$400 $405 |
||||
| Initiated | Neutral | X | ||
| Initiated | Outperform | X | ||
| Initiated | Underperform | X | ||
| Upgrades | Sell Neutral | X | ||
|
$155 $270 |
||||
| Initiated | Buy | X | ||
| Downgrades | Neutral Sell | X | ||
| Reiterated | Outperform | X | ||
|
$170 $250 |
||||
| Reiterated | Buy | X | ||
|
$170 $225 |
||||
| Reiterated | Overweight | X | ||
|
$203 $280 |
||||
| Upgrades | Underperform Mkt Perform | X | ||
| Downgrades | Buy Neutral | X | ||
|
$131 $75 |
||||
| Initiated | Buy | X | ||
| Resumed | Buy | X | ||
| Initiated | Hold | X | ||
| Upgrades | Neutral Buy | X | ||
| Reiterated | Buy | X | ||
|
$313 $228 |
||||
| Initiated | Outperform | X | ||
| Initiated | Neutral | X | ||
| Initiated | Outperform | X | ||
| Initiated | Neutral | X | ||
| Downgrades | Mkt Perform Underperform | X | ||
| Upgrades | In-line Outperform | X | ||
| Initiated | Buy | X | ||
| Downgrades | Buy Neutral | X | ||
| Initiated | Mkt Perform | X | ||
| Downgrades | Outperform In-line | X | ||
| Reiterated | Buy | X | ||
|
$178 $313 |
||||
| Upgrades | Perform Outperform | X | ||
| Reiterated | Buy | X | ||
|
$210 $400 |
||||
| Initiated | Buy | X | ||
| Reiterated | Buy | X | ||
|
$105 $156 |
||||
MDGL Madrigal Pharmaceuticals, Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
